fashion -WSS

fashion

author：explore 2025-09-27 12:21:54 - browse：98129

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Flagship Pioneering launches a new biotech in two countries

focus

WSS

Organ aging and disease risk measured by new blood test

What to do when lifesaving products contribute to climate change

Idaho college killings prosecutors challenge defense's grand jury claims

Idaho college killings prosecutors challenge defense's grand jury claims

Idaho college killings prosecutors challenge defense's grand jury claims

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

leisure time

fashion

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Maui wildfire now ranks as the fifth

Cancer drug shortages should be causing more outrage

30 years of 'Listening to Prozac'

Bright Health sells Medicare Advantage business to Molina

Pediatric cancer treatments threatened by a new FDA policy

Bright Health sells Medicare Advantage business to Molina

Mark Cuban is blaming the wrong people for high drug costs

New air purifier tech could be key to improving indoor air quality

Patients, digital health players weigh in on FTC's data privacy plan

explore

Idaho college killings prosecutors challenge defense's grand jury claims

Indictment alleges Trump's ex

Novo Nordisk touts Wegovy study, but still struggling with supply

ReNAgade cuts staff seven months after raising $300 million

As biotech industry slumps, bioscience job market is upside down

FDA investigates CAR

leisure time

focus

focus

hotspot